Take a trial of UK to unlock this pageFind out more

Scancell Holdings

SCLP 15p 0.0  0.0%
23/09/16 10.00k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 30th Apr 2011 2012 2013 2014 2015 2016 2017E 2018E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p +6.2%

FINANCIAL BRIEF: For the fiscal year ended 30 April 2016, Scancell Holdings Plc revenues was not reported. Net loss increased 7% to L2.6M. Higher net loss reflects Interest receivable and similar income decrease of 90% to L14K (income), Administrative expenses increase of 8% to L1M (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -L0.01. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Apr '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
30th Apr 2017
30th Apr 2018

Price Target: 0.68
(+353.31% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
Broker Consensus Trend
Broker Recommendations for Scancell Holdings
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 0

Named Brokers and Analysts
Panmure Gordon Mike Mitchell , Cenkos Securities ,

Profile Summary

Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects. Its ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system, where inflammation is stimulated at the tumor site and the cytotoxic T-lymphocyte response, where immune system cells are primed to recognize and kill specific cells. The Moditope immunotherapy platform is based on exploiting the normal immune response to stressed cells, mediated by cluster of differentiation 4+ T cells, and harnessing this mechanism to eradicate cancer cells.

Directors: Lindy Durrant (CEO) , Richard Goodfellow (CCE) , Sally Adams (OTH) 54, John Chiplin (NEC) 56, Katherine Cornish-Bowden (NED) 44, Matthew Frohn (NED) , Alan Lewis (NED) 70,

No. of Employees: 10 No. of Shareholders: n/a

Last Annual April 30th, 2016
Last Interim April 30th, 2016
Incorporated April 14, 2008
Shares in Issue 261,558,099
Free Float 212.4m (81.2%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

Address Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom
Web http://www.scancell.co.uk/
Phone +44 115 8231863
Contact ()
Auditors Champion Accountants LLP

SCLP Share Price Performance SCLPQuote
0.0  0.0%
Traded 1:56pm · Minimum 15 min delayed · NMS: 10.00k

Latest SCLP News Announcements (delayed)

Upcoming SCLP Events
Tuesday 18th October, 2016
Scancell Holdings PLC Annual Shareholders Meeting

Recent ↓
Friday 9th September, 2016
Scancell Holdings PLC at Biocentury NewsMakers in the Biotech Industry
Wednesday 14th October, 2015 (estimate)
Scancell Holdings PLC Annual Shareholders Meeting
Tuesday 14th October, 2014
Scancell Holdings PLC Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Should you buy SCLP

Access SCLP Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis